VACV BIOTECH
VacV Biotherapeutics develops an oncolytic virus platform based on the vaccinia virus. The platform genetically modifies the oncolytic virus, which improves its specificity to tumors, reduces neurotoxicity, enhances the therapeutic effect, and greatly increases the production of extracellular enveloped virus (EEV). It has higher safety and efficiency and can be administered by intravenous injection.
VACV BIOTECH
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2022-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.vacvbtx.com
Total Employee:
1+
Status:
Active
Contact:
+44 (0)20 809 07585
Email Addresses:
[email protected]
Total Funding:
3 M USD
Technology used in webpage:
COVID-19 ICUK
Similar Organizations
Accelerbiotics
Accelerbiotics develops sustainable solutions for biotechnology and life science field.
Cell Receptor
Cell Receptor develops a future-oriented therapy for high medical needs: cancer and autoimmune diseases
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
RQ Bio
RQ Bio develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.
Vitarka Therapeutics
Vitarka Therapeutics develops medical technology and solutions for various types of cancer.
Xap Therapeutics
Xap Therapeutics develops synthetic biology-driven platform designed for cell therapeutics.
Investors List
Prox Ventures
Prox Ventures investment in Seed Round - VacV Biotech
Official Site Inspections
http://www.vacvbtx.com Semrush global rank: 10.97 M Semrush visits lastest month: 175
- Host name: server.tuantuan.co.uk
- IP address: 188.240.170.215
- Location: Walsall United Kingdom
- Latitude: 52.5876
- Longitude: -1.9828
- Timezone: Europe/London
- Postal: WS2
More informations about "VacV Biotech"
About us – vacv - VacVbtx.com
VacV was spun out of Barts Cancer Institute, one of the UK’s leading cancer research centers, following over 20 years of pioneering research by cancer immunotherapy pioneer Professor …See details»
VacV Biotech - Crunchbase Company Profile & Funding
Headquarters Regions Europe, Middle East, and Africa (EMEA) Founded Date 2022 Operating Status Active Last Funding Type Seed Also Known As VacV Biotherapeutics Legal Name …See details»
VacV Biotheraputics (UK) Ltd - Patsnap
Explore VacV Biotheraputics (UK) Ltd with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Neoplasms, Endocrinology and Metabolic Disease ...See details»
Our pipeline – vacv - VacVbtx.com
The VacV pipeline comprises of products designed to target multiple cancer types, synergise with conventional therapies such as chemotherapy and radiotherapy and sensitize non-responsive …See details»
VacV Biotherapeutics - LinkedIn
VacV Biotherapeutics | 786 followers on LinkedIn. Developing oncolytic viruses as therapeutics for cancer | VacV Biotherapeutics is a cancer immunotherapy company developing innovative …See details»
VacV Biotherapeutics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for VacV Biotherapeutics. Use the PitchBook Platform to explore the full profile.See details»
VacV Biotherapeutics emerges from stealth mode to bring ground …
London, UK, 26 October 2022 – VacV Biotherapeutics (“VacV” or “the Company”), a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth …See details»
VacV Biotherapeutics emerges from stealth mode to bring
Oct 26, 2022 VacV Biotherapeutics emerges from stealth mode to bring ground-breaking cancer immunotherapies to the clinic Enhanced systemic delivery system using novel Vaccinia virus …See details»
VacV Biotheraputics (UK) Ltd. - VentureRadar
"VacV Biotherapeutics is a cancer immunotherapy company developing innovative viral-based therapies for cancers. Launched in 2022 by cancer immunotherapy pioneers Professor Yaohe …See details»
VacV - 446 Competitors and Alternatives - Tracxn
Dec 5, 2024 VacV - Developer of immuno-therapeutics for cancer treatment. Raised a total funding of $3M over 1 round from 1 investor.See details»
VacV Biotherapeutics emerges from stealth mode to bring ground …
London, UK, 26 October 2022 – VacV Biotherapeutics (“VacV” or “the Company”), a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth …See details»
VacV Biotherapeutics (UK) Funding: $3M - medicalstartups.org
MedicalStartups 756 followers November 26, 2024 Converge Bio raises $5.5M to expedite drug discovery, development with GenAI Follow Page Add Startup See also:See details»
Our Science – vacv - VacVbtx.com
The VacV platform, comprises a rationally engineered Vaccinia virus with enhanced capacity for immune induction and systemic spread. It has the potential to revolutionise the current …See details»
Seed Round - VacV Biotech - 2022-01-01 - Crunchbase
Overview Organization Name VacV Biotech Announced Date Jan 1, 2022 Funding Type Seed Funding Stage Seed Money Raised $3MSee details»
VacV Biotech - EU-Startups
VacV is a cancer immunotherapy company developing viral-based therapies for cancer. Its promising pipeline of easy-to-administer treatments includes features that offer significant …See details»
VacV Biotherapeutics emerges from stealth mode to bring
Oct 26, 2022 PRESS RELEASE VacV Biotherapeutics emerges from stealth mode to bring ground-breaking cancer immunotherapies to the clinic Enhanced systemic delivery system …See details»
Privacy Policy – vacv - VacVbtx.com
This privacy notice contains information about what data we collect and store about you and why. It also tells you who we share this information with, the security mechanisms we have put in …See details»
News – vacv - VacVbtx.com
VacV was awarded Innovate UK Grant on 10/09/2024: “Transforming Cancer Therapeutics: Preclinical development of a systemically deliverable oncolytic Vaccinia Virus for treatment of …See details»
Publications – vacv - VacVbtx.com
Authors : Dr Renato Brito Baleeiro, Dr Peng Liu, Dr Louisa S Chard Dunmall, Dr Carmela Di Gioia, Dr Ai Nagano, Dr Lauren Cutmore , Dr Jun Wang, Prof. Claude Chelala, Dr Lydon …See details»